ProMetic Life Sciences Inc. (PLI) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Posted by on Apr 22nd, 2017

ProMetic Life Sciences Inc. (TSE:PLI) posted its earnings results on Thursday. The company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.04. The firm earned $4.11 million during the quarter.

ProMetic Life Sciences (TSE:PLI) traded up 0.47% during mid-day trading on Friday, reaching $2.13. 451,676 shares of the company traded hands. ProMetic Life Sciences has a one year low of $1.47 and a one year high of $3.49. The firm’s market cap is $1.42 billion. The stock’s 50-day moving average price is $2.25 and its 200-day moving average price is $2.36.

ILLEGAL ACTIVITY NOTICE: “ProMetic Life Sciences Inc. (PLI) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://transcriptdaily.com/2017/04/22/prometic-life-sciences-inc-pli-releases-quarterly-earnings-results-beats-expectations-by-0-04-eps.html.

In other ProMetic Life Sciences news, insider Bruce Pritchard acquired 15,300 shares of the business’s stock in a transaction dated Friday, April 7th. The shares were acquired at an average price of C$2.18 per share, with a total value of C$33,354.00. In the last three months, insiders bought 26,510 shares of company stock worth $56,263.

Several research analysts have commented on PLI shares. Royal Bank of Canada decreased their target price on shares of ProMetic Life Sciences from C$4.25 to C$4.00 and set an “outperform” rating for the company in a research report on Monday, April 3rd. Scotiabank restated an “outperform” rating and issued a C$5.00 target price on shares of ProMetic Life Sciences in a research report on Thursday, February 23rd. Finally, TD Securities set a C$4.50 target price on shares of ProMetic Life Sciences and gave the stock a “speculative buy” rating in a research report on Monday, April 3rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of C$4.63.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.